Suppr超能文献

建立并验证一种 LC-MS/MS 方法以定量检测小鼠血浆和脑微透析液中的溴结构域和末端外结构域(BET)抑制剂 JQ1:在脑微透析研究中的应用。

Development and validation of an LC-MS/MS method to quantify the bromodomain and extra-terminal (BET) inhibitor JQ1 in mouse plasma and brain microdialysate: Application to cerebral microdialysis study.

机构信息

Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.

Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.

出版信息

J Pharm Biomed Anal. 2021 Sep 10;204:114274. doi: 10.1016/j.jpba.2021.114274. Epub 2021 Jul 21.

Abstract

JQ1, is a cell-permeable small-molecule inhibitor of bromodomain and extra-terminal protein (BET) function with reportedly good CNS penetration, however, unbound and pharmacologically active CNS JQ1 exposures have not been characterized. Additionally, no quantitative bioanalytical methods for JQ1 have been described in the literature to support the CNS penetration studies. In the present article, we discuss the development and validation of a sensitive and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) quantitative methods to determine JQ1 in mouse plasma and brain microdialysate. JQ1 and the internal standard, dabrafenib (ISTD), were extracted from plasma and microdialysate samples using a simple solid phase extraction protocol performed on an Oasis HLB μElution plate. Chromatographic separation of JQ1 and ISTD was achieved on a reversed phase C analytical column with gradient elution profile of mobile phases (MP A: water containing 0.1 % formic acid and MP B: acetonitrile containing 0.1 % formic acid) at a flow rate of 0.6 mL/min. The mass spectrometric detection was performed in the positive MRM ion mode by monitoring the transitions 457.40 > 341.30 (JQ1) and 520.40 > 307.20 (ISTD). The calibration curves demonstrated good linearities over the concentration range of 5-1000 ng/mL for the mouse plasma method (r ≥ 0.99) and 0.5-500 ng/mL for the microdialysate method (r ≥ 0.99). The experimental limit of quantification obtained was 5 and 0.5 ng/mL for the mouse plasma and microdialysate method, respectively, with the coefficient of variation less than 10 % for the analyte peak area. All the other validation parameters, including intra-and inter-day accuracy and precision, matrix effect, selectivity, carryover effect, and stability, were within the USFDA bioanalytical guidelines acceptance limits. The LC-MS/MS method was successfully applied to a mouse pharmacokinetic and cerebral microdialysis study to characterize the unbound JQ1 exposure in brain extracellular fluid and plasma.

摘要

JQ1 是一种细胞通透性的小分子抑制剂,可抑制溴结构域和末端外蛋白(BET)的功能,据称其具有良好的中枢神经系统穿透性,然而,未结合的和具有药理活性的中枢神经系统 JQ1 暴露情况尚未得到描述。此外,文献中尚未描述用于支持中枢神经系统穿透研究的 JQ1 的定量生物分析方法。在本文中,我们讨论了开发和验证一种灵敏且可靠的液相色谱-串联质谱(LC-MS/MS)定量方法,以测定小鼠血浆和脑微透析液中的 JQ1。JQ1 和内标 dabrafenib(ISTD)使用 Oasis HLB μElution 板上的简单固相萃取方案从血浆和微透析液样品中提取。JQ1 和 ISTD 的色谱分离在反相 C 分析柱上实现,采用流动相(MP A:含 0.1%甲酸的水和 MP B:含 0.1%甲酸的乙腈)的梯度洗脱程序,流速为 0.6mL/min。质谱检测采用正 MRM 离子模式,通过监测 457.40 > 341.30(JQ1)和 520.40 > 307.20(ISTD)的跃迁进行。小鼠血浆方法的校准曲线在 5-1000ng/mL 浓度范围内表现出良好的线性关系(r≥0.99),微透析液方法的校准曲线在 0.5-500ng/mL 浓度范围内表现出良好的线性关系(r≥0.99)。小鼠血浆和微透析液方法的实验定量下限分别为 5 和 0.5ng/mL,分析物峰面积的变异系数小于 10%。所有其他验证参数,包括日内和日间精密度和准确度、基质效应、选择性、残留效应和稳定性,均符合美国 FDA 生物分析指南的可接受标准。LC-MS/MS 方法成功应用于小鼠药代动力学和脑微透析研究,以描述脑细胞外液和血浆中未结合的 JQ1 暴露情况。

相似文献

4
Application of a LC-MS/MS method for evaluating lung penetration of tobramycin in rats by microdialysis.
J Pharm Biomed Anal. 2017 Feb 5;134:340-345. doi: 10.1016/j.jpba.2016.10.023. Epub 2016 Oct 27.
5
An LC/MS quantitative and microdialysis method for cyclovirobuxine D pharmacokinetics in rat plasma and brain: The pharmacokinetic comparison of three different drug delivery routes.
J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Oct 1;1002:185-93. doi: 10.1016/j.jchromb.2015.08.022. Epub 2015 Aug 24.
10
Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of goserelin in rabbit plasma.
J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Aug 15;878(24):2235-42. doi: 10.1016/j.jchromb.2010.06.031. Epub 2010 Jul 1.

本文引用的文献

2
CNS penetration and pharmacodynamics of the CHK1 inhibitor prexasertib in a mouse Group 3 medulloblastoma model.
Eur J Pharm Sci. 2020 Jan 15;142:105106. doi: 10.1016/j.ejps.2019.105106. Epub 2019 Oct 25.
3
Resolving medulloblastoma cellular architecture by single-cell genomics.
Nature. 2019 Aug;572(7767):74-79. doi: 10.1038/s41586-019-1434-6. Epub 2019 Jul 24.
4
Medulloblastoma.
Nat Rev Dis Primers. 2019 Feb 14;5(1):11. doi: 10.1038/s41572-019-0063-6.
5
6
Small-molecule inhibition of BRDT for male contraception.
Cell. 2012 Aug 17;150(4):673-84. doi: 10.1016/j.cell.2012.06.045.
7
Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation.
Clin Cancer Res. 2011 Jan 1;17(1):89-99. doi: 10.1158/1078-0432.CCR-10-1934. Epub 2010 Nov 18.
8
Selective inhibition of BET bromodomains.
Nature. 2010 Dec 23;468(7327):1067-73. doi: 10.1038/nature09504. Epub 2010 Sep 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验